Thư viện tập trung - Thư viện điện tử

Sách, tuyển tập

Tài liệu điện tử

Can type 2 diabetes and its associated complications be prevented or delayed in people with intermediate hyperglycaemia? Summary / Stinton, Chris;Herath, Deshani;Parr, Janette;Mansbridge, Alice;Williams, Hannah;Rotar, Oxana;Grove, Amy;Al-Khudairy, Lena;Kudrna, Laura;A. Johnson, Samantha;Oyebode, Oyinlola;Taylor-Phillips, Sian

Tác giả : Stinton, Chris;Herath, Deshani;Parr, Janette;Mansbridge, Alice;Williams, Hannah;Rotar, Oxana;Grove, Amy;Al-Khudairy, Lena;Kudrna, Laura;A. Johnson, Samantha;Oyebode, Oyinlola;Taylor-Phillips, Sian

Nhà xuất bản : World Health Organization. Regional Office for Europe

Năm xuất bản : 2024

Chủ đề : 1. Diabetes Mellitus, Type 2. 2. Population. 3. Public Health Practice. 4. Randomized Controlled Trial. 5. Systematic Review. 6. Publications.

Chia sẻ

Thông tin chi tiết

Tóm tắt :

3 p. Diabetes affects one in 11 adults in the WHO European Region. It is a key risk factor for cardiovascular diseases, kidney failure, vision loss and nerve damage. Intermediate hyperglycaemia is a state in which blood glucose levels are above the normal range but below the threshold for diabetes. It is associated with an increased risk for type 2 diabetes, obesity, cardiovascular diseases and mortality. This review assessed the effects of interventions for people with intermediate hyperglycaemia. Results from randomized controlled trials indicate that the risk of developing type 2 diabetes in people with intermediate hyperglycaemia is reduced by lifestyle and (some) pharmacological interventions. Most of the available evidence did not find a difference in mortality or other serious health outcomes for either pharmacological or lifestyle interventions. However, the follow-up periods may have been too short for health outcomes to have emerged. The current evidence suggests that the risk of developing type 2 diabetes is reduced through intervention at the point of in

Chia sẻ

Hiển thị MARC

Thông tin dữ liệu nguồn

Thư viện	Ký hiệu xếp giá	Dữ liệu nguồn
Tổ chức y tế thế giới		https://iris.who.int/handle/10665/378142

Ldr		00025nam a2200024 a 4500
001		CLN251847820
041	__	$aen
100	__	$aStinton, Chris
245	__	$aCan type 2 diabetes and its associated complications be prevented or delayed in people with intermediate hyperglycaemia? Summary /$cStinton, Chris;Herath, Deshani;Parr, Janette;Mansbridge, Alice;Williams, Hannah;Rotar, Oxana;Grove, Amy;Al-Khudairy, Lena;Kudrna, Laura;A. Johnson, Samantha;Oyebode, Oyinlola;Taylor-Phillips, Sian
260	__	$bWorld Health Organization. Regional Office for Europe ,$c2024
520	__	$a3 p.
520	__	$aDiabetes affects one in 11 adults in the WHO European Region. It is a key risk factor for cardiovascular diseases, kidney failure, vision loss and nerve damage. Intermediate hyperglycaemia is a state in which blood glucose levels are above the normal range but below the threshold for diabetes. It is associated with an increased risk for type 2 diabetes, obesity, cardiovascular diseases and mortality. This review assessed the effects of interventions for people with intermediate hyperglycaemia. Results from randomized controlled trials indicate that the risk of developing type 2 diabetes in people with intermediate hyperglycaemia is reduced by lifestyle and (some) pharmacological interventions. Most of the available evidence did not find a difference in mortality or other serious health outcomes for either pharmacological or lifestyle interventions. However, the follow-up periods may have been too short for health outcomes to have emerged. The current evidence suggests that the risk of developing type 2 diabetes is reduced through intervention at the point of in
650	_2	$aSystematic Review
650	_2	$aDiabetes Mellitus, Type 2
650	_2	$aPopulation
650	_2	$aPublic Health Practice
650	_2	$aRandomized Controlled Trial
655	__	$aPublications
700	__	$aHerath, Deshani
700	__	$aParr, Janette
700	__	$aMansbridge, Alice
700	__	$aWilliams, Hannah
700	__	$aRotar, Oxana
700	__	$aGrove, Amy
700	__	$aAl-Khudairy, Lena
700	__	$aKudrna, Laura
700	__	$aA. Johnson, Samantha
700	__	$aOyebode, Oyinlola
700	__	$aTaylor-Phillips, Sian
856	__	$uhttps://iris.who.int/handle/10665/378142
900		1
907		https://iris.who.int/bitstream/handle/10665/378142/WHO-EURO-2024-10170-49942-75075-eng.pdf.jpg?sequence=4&isAllowed=y
925		G
926		0
927		SH

Thông tin dữ liệu nguồn

Tài liệu cùng tác giả

Lời ngỏ

Mục đích và phương châm hoạt động

Bản quyền